Greenphire

Greenphire, Ernst & Young form strategic partnership

Tuesday, July 9, 2013 03:08 PM

Greenphire, a provider of payment technologies for the clinical trials industry, has launched a strategic partnership with Ernst & Young (E&Y) to combine Greenphire’s eClinicalGPS technology with the global intellectual property and expertise of E&Y’s advisory practice for clients in the pharmaceutical industries.

More... »

Greenphire, Oracle integrate product suites

Friday, June 28, 2013 02:19 PM

Greenphire, a provider of payment technologies for the clinical trials industry, has partnered with Oracle Health Sciences to integrate their respective product suites to streamline and automate processes from trial planning and budgeting through data capture to executing payments to  sites and patients, while providing real-time reporting and analytics.

More... »

Greenphire, IMS Health integrate eClinicalGPS and GrantPlan

Wednesday, June 19, 2013 11:49 AM

Greenphire has launched a strategic integration of its eClinicalGPS, a global investigator payment technology, with IMS Health’s GrantPlan, a benchmarking and contracting tool for global clinical site grants.

More... »

Greenphire CEO selected as finalist in Ernst & Young Entrepreneur of the Year Awards

Wednesday, May 22, 2013 08:00 AM

Greenphire, a of payment technologies for the clinical trials industry, announced that the company's CEO, Sam Whitaker, has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.

More... »

Greenphire opens London office to facilitate expansion in Europe

Wednesday, May 8, 2013 10:38 AM

Greenphire, a provider of payment technologies for the clinical trials industry, has expanded into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and is designed to support the increasing global demand for Greenphire’s products and services.

More... »

N30 Pharma selects Greenphire's payment tech for cystic fibrosis study

Monday, April 22, 2013 12:16 PM

N30 Pharmaceuticals will use Greenphire's global payment technology platforms, eClinicalGPS and ClinCard, to streamline payments to investigators and subjects throughout its phase Ia/IIb cystic fibrosis study that began in March.

More... »

Greenphire chosen for long-term global trial

Wednesday, November 7, 2012 09:17 AM

King of Prussia, Penn.-based Greenphire, a provider of payment technologies for the clinical trials industry, said its ClinCard Technology Platform has been chosen for use in a large, phase III clinical trial to include more than 1,000 patients across six countries. The trial is expected to last more than five years. 

More... »

CHDI Foundation selects Greenphire technology for global clinical payment

Friday, June 1, 2012 12:42 PM

CHDI Foundation, a non-profit biomedical research organization focused on Huntington’s disease (HD), will be implementing Philadelphia-based Greenphire’s two flagship payment technology platforms, eClinicalGPS and ClinCard System, to enhance its payment capability in the upcoming Enroll-HD global observational study.

More... »

Greenphire partners with Merge Healthcare

Thursday, January 19, 2012 01:05 PM

Greenphire has formed an exclusive strategic partnership with the clinical trials division of Merge Healthcare to offer integrated functionality between Merge’s EDC technology and Greenphire’s eClinicalGPS site and vendor payment management technology.

More... »

Almac, Greenphire collaborate in direct patient payment services

Thursday, October 6, 2011 11:39 AM

The Almac Group and Greenphire have reported that Almac’s Clinical Technologies business unit, the provider of IXRS (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive alliance with Greenphire to offer joint services relating to patient payment administration for clinical trials. This new service improves current methods of manual patient payment management and alleviates administrative burden on personnel in biopharmaceutical companies and contract research organizations, allowing them to focus on more study-specific responsibilities.

More... »